Article

Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults

Division of Infectious Diseases, University of Florida Health Science Center, Jacksonville, Florida 32206, USA.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases (Impact Factor: 2.33). 09/2008; 12(6):e77-83. DOI: 10.1016/j.ijid.2008.05.1226
Source: PubMed

ABSTRACT Vaccination against hepatitis B virus (HBV) has been recommended for all high-risk adults since 1982. Since the advent of highly active antiretroviral therapy, few studies have examined adherence to the Infectious Diseases Society of America (IDSA) and Advisory Committee on Immunization Practices (ACIP) guidelines for hepatitis B vaccination in persons infected with HIV.
This was a seven-year retrospective, cross-sectional analysis of HBV vaccination practices in HIV-1-positive adults treated in an urban ambulatory care center. Compliance with screening, hepatitis B vaccination recommendations, and response to vaccination were assessed.
Of the 1601 charts reviewed, 717 persons were eligible for vaccination against hepatitis B. Of these patients, 503 received at least one dose of vaccine, but only 356 patients completed the three-dose series. Vaccine response was associated with CD4 count (p=0.006) and viral load (p=0.001) at the time of the first dose. However, development of hepatitis B surface antibody was seen at all CD4 counts and viral loads. The multivariate analysis showed only the HIV viral load was predictive of immunologic response. Twenty of the vaccine-eligible patients who did not receive vaccination were infected with HBV during the study period. No vaccinated persons contracted hepatitis B.
Failure to implement these guidelines represents a missed opportunity to prevent disease. In our study, HIV viral load was better than CD4 count as a predictor of response to the HBV vaccination. However, neither low CD4 count nor high HIV viral load should be used as justification to delay vaccination of high-risk persons.

0 Followers
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B vaccine has been recommended for use in people living with HIV (PLHIV) mostly because of the similarities in routes of infection and their prevalence in the same geographic areas. PLHIV may not develop sero-protection after receiving standard hepatitis B vaccine due to their compromised immune status.
    Cochrane database of systematic reviews (Online) 10/2014; 10(10):CD009886. DOI:10.1002/14651858.CD009886.pub2 · 5.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Due to the shared modes of transmission, coinfection with HBV and human immunodeficiency virus (HIV) is not uncommon. It is estimated that 10% of HIV-infected patients worldwide are coinfected with HBV. In areas where an HBV vaccination program is implemented, the HBV seroprevalence has declined significantly. In HIV/HBV-coinfected patients, HBV coinfection accelerates immunologic and clinical progression of HIV infection and increases the risk of hepatotoxicity when combination antiretroviral therapy (cART) is initiated, while HIV infection increases the risk of hepatitis events, cirrhosis, and end-stage liver disease related to chronic HBV infection. With the advances in antiviral therapy, concurrent, successful long-term suppression of HIV and HBV replication can be achieved in the cART era. To reduce the disease burden of HBV infection among HIV-infected patients, adoption of safe sex practices, avoidance of sharing needles and diluent, HBV vaccination and use of cART containing tenofovir disoproxil fumarate plus emtricitabine or lamivudine are the most effective approaches. However, due to HIV-related immunosuppression, using increased doses of HBV vaccine and novel approaches to HBV vaccination are needed to improve the immunogenicity of HBV vaccine among HIV-infected patients.
    World Journal of Gastroenterology 10/2014; 20(40):14598-14614. DOI:10.3748/wjg.v20.i40.14598 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We identified factors associated with complete hepatitis B vaccination of patients with HIV.

Preview

Download
0 Downloads
Available from